Light chain amyloidosis 2012

A new era

Moshe E. Gatt, Giovanni Palladini

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

AL amyloidosis patients with multi-organ and particularly cardiac involvement have historically been considered to have a bad prognosis. The introduction of autologous stem cell transplantation was associated with unacceptable toxicity in high-risk patients, but responding patients have prolonged overall survival. Toxicities can be decreased by careful patient selection, but this reduces the applicability of this treatment modality to a limited number of patients. Efforts are therefore needed to design novel more effective regimens, with the use of new medications, such as thalidomide, lenalidomide and bortezomib, next generation immunomodulatory drugs and proteasome inhibitors. Their combination with dexamethasone and alkylating agents show promising results, allowing a high percentage of remission and subsequent event-free and overall survival, even in a significant proportion of high risk, poor prognosis populations. This review includes the state-of-the-art treatment for AL amyloidosis patients as of 2012, in light of the progress in management of this disease during recent years.

Original languageEnglish
Pages (from-to)582-598
Number of pages17
JournalBritish Journal of Haematology
Volume160
Issue number5
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Amyloidosis
Light
Proteasome Inhibitors
Thalidomide
Alkylating Agents
Stem Cell Transplantation
Disease Management
Patient Selection
Dexamethasone
Disease-Free Survival
Survival
Therapeutics
Pharmaceutical Preparations
Population

Keywords

  • Amyloidosis
  • Novel agents
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Light chain amyloidosis 2012 : A new era. / Gatt, Moshe E.; Palladini, Giovanni.

In: British Journal of Haematology, Vol. 160, No. 5, 03.2013, p. 582-598.

Research output: Contribution to journalArticle

Gatt, Moshe E. ; Palladini, Giovanni. / Light chain amyloidosis 2012 : A new era. In: British Journal of Haematology. 2013 ; Vol. 160, No. 5. pp. 582-598.
@article{f24bc3d8fe544972b660d842f254321e,
title = "Light chain amyloidosis 2012: A new era",
abstract = "AL amyloidosis patients with multi-organ and particularly cardiac involvement have historically been considered to have a bad prognosis. The introduction of autologous stem cell transplantation was associated with unacceptable toxicity in high-risk patients, but responding patients have prolonged overall survival. Toxicities can be decreased by careful patient selection, but this reduces the applicability of this treatment modality to a limited number of patients. Efforts are therefore needed to design novel more effective regimens, with the use of new medications, such as thalidomide, lenalidomide and bortezomib, next generation immunomodulatory drugs and proteasome inhibitors. Their combination with dexamethasone and alkylating agents show promising results, allowing a high percentage of remission and subsequent event-free and overall survival, even in a significant proportion of high risk, poor prognosis populations. This review includes the state-of-the-art treatment for AL amyloidosis patients as of 2012, in light of the progress in management of this disease during recent years.",
keywords = "Amyloidosis, Novel agents, Prognosis, Therapy",
author = "Gatt, {Moshe E.} and Giovanni Palladini",
year = "2013",
month = "3",
doi = "10.1111/bjh.12191",
language = "English",
volume = "160",
pages = "582--598",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "5",

}

TY - JOUR

T1 - Light chain amyloidosis 2012

T2 - A new era

AU - Gatt, Moshe E.

AU - Palladini, Giovanni

PY - 2013/3

Y1 - 2013/3

N2 - AL amyloidosis patients with multi-organ and particularly cardiac involvement have historically been considered to have a bad prognosis. The introduction of autologous stem cell transplantation was associated with unacceptable toxicity in high-risk patients, but responding patients have prolonged overall survival. Toxicities can be decreased by careful patient selection, but this reduces the applicability of this treatment modality to a limited number of patients. Efforts are therefore needed to design novel more effective regimens, with the use of new medications, such as thalidomide, lenalidomide and bortezomib, next generation immunomodulatory drugs and proteasome inhibitors. Their combination with dexamethasone and alkylating agents show promising results, allowing a high percentage of remission and subsequent event-free and overall survival, even in a significant proportion of high risk, poor prognosis populations. This review includes the state-of-the-art treatment for AL amyloidosis patients as of 2012, in light of the progress in management of this disease during recent years.

AB - AL amyloidosis patients with multi-organ and particularly cardiac involvement have historically been considered to have a bad prognosis. The introduction of autologous stem cell transplantation was associated with unacceptable toxicity in high-risk patients, but responding patients have prolonged overall survival. Toxicities can be decreased by careful patient selection, but this reduces the applicability of this treatment modality to a limited number of patients. Efforts are therefore needed to design novel more effective regimens, with the use of new medications, such as thalidomide, lenalidomide and bortezomib, next generation immunomodulatory drugs and proteasome inhibitors. Their combination with dexamethasone and alkylating agents show promising results, allowing a high percentage of remission and subsequent event-free and overall survival, even in a significant proportion of high risk, poor prognosis populations. This review includes the state-of-the-art treatment for AL amyloidosis patients as of 2012, in light of the progress in management of this disease during recent years.

KW - Amyloidosis

KW - Novel agents

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84873993447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873993447&partnerID=8YFLogxK

U2 - 10.1111/bjh.12191

DO - 10.1111/bjh.12191

M3 - Article

VL - 160

SP - 582

EP - 598

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 5

ER -